Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device Launches

New Products In Brief

This article was originally published in The Gray Sheet

Executive Summary

FDA clears skin-cancer companion diagnostic. Medtronic announces two AAA-related approvals. OrbusNeich launches dual-therapy stent outside the U.S. More new products.

You may also be interested in...



Research In Brief

Exact Sciences’ and Genomic Health announce favorable results for colon cancer tests. Boston Scientific launches trial of MRI-safe pacemaker. More research news.

News In Brief

Hologic buys Interlace for MyoSure

House Health Subcommittee Chair Prioritizes Affordability, Innovation, Ending COVID PHE

Kentucky Republican Brett Guthrie is strong proponent of health care affordability and innovation in pharmaceuticals and medical devices. He’s also monitoring FDA’s response to drug shortages and infant formula shortages.

Table

View full table

Topics

Related Companies

Tags:
Medical Device Launches
Latest Headlines

Philips Healthcare Doubles Down On Creating An Agile Future

CDRH 2022: Shuren Says COVID-19 Left Agency ‘Battle-Scarred’ But Also Wiser

Women’s Health Expert Panel Addresses Challenges, Opportunities In Post-Roe Era

The Serious Business Of Digital Medical Games

See All
UsernamePublicRestriction

Register

MT032117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By